EcoSynthetix’s third-quarter update combines a steep sales decline with near-break-even adjusted EBITDA and a new commercial account. EPS was slightly negative, but the available estimate isn’t a reliable basis for a beat-or-miss comparison.
EcoSynthetix Inc. (TSX: ECO) reported results after market close on November 3, 2026, for the quarter ended September 30. The earnings calendar lists EPS of -C$0.0062 and a consensus estimate of -C$0.01 from one analyst. Both figures indicate a small loss, but they may follow different reporting conventions, so they aren’t directly comparable. Supplemental company-results headlines report sales of US$3.6 million, down 38% from a year earlier, and near-break-even adjusted EBITDA. These figures come from headlines, not the supplied earnings calendar. For more company information, see the ECO stock page.
Recent earnings trend
EcoSynthetix Inc
ECO.TO
ECO.TO
EcoSynthetix Inc
WealthAwesomeMarket cap
$98.76M
52W high
$5.00
52W low
$1.26
1W change
+18.31%
Beta
0.58
Analyst Price Targets
Based on analyst covering ECO · as of Sep 17, 2026
Wall Street analysts forecast ECO stock price to rise 399.4% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$8.39
+399.4% Upside
Current Price
C$1.68
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on ECO's historical volatility
30-Day Vol
87.5%
Annualized
90-Day Vol
68.8%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$1.41
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$1.58 | C$1.17 – C$2.14 |
| 60 trading days | C$1.49 | C$0.97 – C$2.29 |
| 90 trading days | C$1.41 | C$0.83 – C$2.37 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Analyst coverage: 1 analyst(s) cover this name; upcoming EPS consensus is available.
| Fiscal period | Report date | Actual EPS | Estimate | Surprise |
|---|---|---|---|---|
| 2026-09-30 | 2026-11-03 | -0.0062 | — | — |
| 2026-06-30 | 2026-07-28 | -0.0101 | — | — |
| 2026-03-31 | 2026-05-07 | -0.0138 | — | — |
| 2025-12-31 | 2026-02-19 | 0.0036 | — | — |
| 2025-09-30 | 2025-11-06 | -0.0021 | — | — |
| 2025-06-30 | 2025-07-29 | 0.0026 | — | — |
Investor takeaway: Sales fell sharply, while the company showed signs of commercial progress and cost control. A new account with a global top-five tissue producer could lead to recurring orders, but one account announcement doesn’t prove a turnaround. The calendar lists an EPS consensus of -C$0.01 from one analyst, unchanged over the past 30 days. Its revenue consensus was US$4.14 million, with estimated year-over-year growth of -7.4%. The US$3.6 million sales figure in supplemental headlines is below that estimate. But differences in currency and sources mean investors should check the company’s filing before comparing them directly. ECO remains loss-making in the supplied snapshot, with trailing-twelve-month EPS of -C$0.03 and a profit margin of -6.31%.
US$3.6 million in reported Q3 sales
Supplemental headlines report that third-quarter sales fell 38% from a year earlier. The earnings calendar lists revenue consensus of US$4.14 million from one analyst. It also lists actual EPS of -C$0.0062 against consensus of -C$0.01, but that estimate isn’t confirmed as a comparable benchmark. The auto-inserted earnings trend table offers historical context. The supplied data shows no beats in the last four comparable quarters.
Bull case
Near-break-even adjusted EBITDA, according to supplemental headlines, suggests EcoSynthetix may be keeping operating losses in check despite lower sales. The company also announced a new account with a global top-five tissue producer. Its second-quarter update mentioned ongoing trials with major pulp, tissue and packaging producers. If those trials lead to repeat orders and sales volumes recover, commercial progress could improve revenue. The company also reported US$29.4 million in cash and term deposits, which could provide a buffer. Investors should confirm that figure in the financial statements.
Bear case
A 38% year-over-year sales decline is a serious warning sign. The earnings calendar’s revenue consensus already pointed to a 7.4% decline. A new account or customer trial doesn’t guarantee significant sales, and near-break-even adjusted EBITDA isn’t the same as positive net income. ECO’s trailing-twelve-month loss and negative profit margin show that profitability remains unproven. Shares closed at C$1.68, below the 50-day moving average of C$1.86 and the 200-day average of C$2.88. They also remain well below the 52-week high of C$5.00. A gain over the past week doesn’t erase the decline over the past month.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
